bendamustine / Generic mfg. - LARVOL DELTA

Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 study. (PubMed, Lancet Haematol) - P3 | "Although the pre-specified primary outcome of the trial was not met, the favourable safety profile suggests that azacitidine could add to the treatment options in these difficult to treat diseases especially in combination with other drugs. Trials with combination are in preparation in a platform trial."

Clinical • IO biomarker • Journal • P3 data • P3 data • Candidiasis • Cardiovascular • Congestive Heart Failure • Follicular Lymphoma • Gastrointestinal Disorder • Heart Failure • Hematological Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Novel Coronavirus Disease • Oncology • T Cell Non-Hodgkin Lymphoma • BCL6 • CXCL13 • ICOS • MME • PD-1

POLATUZUMAB VEDOTIN, RITUXIMAB, GEMCITABINE AND OXALIPLATIN (POLA-R-GEMOX) FOR RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): RESULTS FROM THE RANDOMIZED PHASE III POLARGO TRIAL (EHA 2025) - P3 | "Background: Polatuzumab vedotin is approved in frontline and R/R DLBCL, with the latter involving a combination with bendamustine and rituximab (Tilly H, et al. This study met its primary and all key secondary endpoints. Pola-R-GemOx demonstrated a statistically significant and clinically meaningful benefit in OS and PFS, with a 40% reduction in risk of death relative to R-GemOx. Pola-R-GemOx was associated with known risks of individual components, including PN and infection, but neither significantly impacted study endpoints."

Clinical • P3 data • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Indolent Lymphoma • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Pain • Thrombocytopenia

Three-Year Efficacy and Longitudinal Safety of Lisocabtagene Maraleucel (liso-cel) in Patients With Third-Line or Later (3L+) Follicular Lymphoma (FL) From TRANSCEND FL (ASH 2025) - P2 | "In patients with 3L+ FL, a single infusion of liso-cel demonstrated remarkable efficacy, withdurable responses and high 3-year survival rates, regardless of POD24 status or prior bendamustineexposure. No new safety signals were identified. Grade ≥3 neutropenia and hypogammaglobulinemiadecreased over time and severe infections remained low, further underscoring the favorable long-termsafety profile of liso-cel in patients with 3L+ FL."

Clinical • Follicular Lymphoma • Hematological Malignancies • Infectious Disease • Lymphoma • Neutropenia

Contemporary Treatment and Survival Outcomes in Mantle Cell Lymphoma: A National Real-World Analysis From REALYSA, a LYSA Cohort. (PubMed, Hematol Oncol) - P=N/A | "Older patients were treated with bendamustine-rituximab (28%), R-CHOP (18%), and low-dose cytarabine (20%)...In the second-line setting (n = 72), most patients were POD24 (89%) and 56% received ibrutinib, yet outcomes remained poor (CR 24%, ORR 35%, median EFS and OS of 6.3 and 25.6 months, respectively). These findings underscore the need for improved strategies for older and high-risk patients. Retrospective landmark analyses suggest a potential association between RM and improved EFS but are limited by baseline differences between groups."

Journal • Real-world evidence • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Oncology

Diffuse Large B-cell Lymphoma (ASH 2026) - "He will consider where approved treatments such as polatuzumab vedotin in combination with bendamustine-rituximab, loncastuximab tesirine, tafasitamab-lenalidomide, and brentuximab vedotin with lenalidomide-rituximab fit into current management algorithms. He will also discuss promising agents under investigation, including novel therapies targeting B-cell receptor signaling, apoptosis, and lineage-restricted transcription factors. This talk will also review combination strategies being explored to overcome treatment resistance."

B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma

Fixed-duration VenO vs FCR/BR in fit patients with untreated CLL: primary analysis of the phase 3 CRISTALLO trial. (PubMed, Blood) - P3 | "The phase 3 CRISTALLO trial (NCT04285567) compared first-line fixed-duration venetoclax-obinutuzumab (VenO) vs fludarabine, cyclophosphamide, and rituximab (FCR)/bendamustine-rituximab (BR) in patients with chronic lymphocytic leukemia, using undetectable minimal residual disease (uMRD) as the sole primary endpoint. No patient in the VenO arm was deemed high-risk for tumor lysis syndrome following obinutuzumab debulking; no clinical TLS occurred. These results confirm and extend the findings from the GAIA-CLL13 trial, validating increased depth of response with VenO vs chemoimmunotherapies."

IO biomarker • Journal • P3 data • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • TP53

Acalabrutinib, venetoclax and obinutuzumab in relapsed CLL: Final efficacy and ctDNA analysis of the CLL2-BAAG trial. (PubMed, Blood) - P2 | "The phase 2 CLL2-BAAG trial tested the measurable residual disease (MRD)-guided triple combination of acalabrutinib, venetoclax and obinutuzumab after an optional bendamustine debulking in 45 patients with relapsed/refractory CLL (one patient was excluded from the analysis due to a violation of exclusion criteria). The addition of ctDNA-based analyses to FCM MRD assessment seems to improve early detection of relapses. ClinicalTrials.gov Identifier: NCT03787264."

Circulating tumor DNA • Journal • Oncology • IGH • TP53

MorningLyte: Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5 (clinicaltrials.gov) - P3 | N=790 | Active, not recruiting | Sponsor: The Lymphoma Academic Research Organisation | Recruiting ➔ Active, not recruiting

Enrollment closed • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Oncology • CD20

Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia. (PubMed, N Engl J Med) - P3 | "Acalabrutinib-venetoclax with or without obinutuzumab significantly prolonged progression-free survival as compared with chemoimmunotherapy in fit patients with previously untreated CLL. (Funded by AstraZeneca; AMPLIFY ClinicalTrials.gov number, NCT03836261.)."

Clinical • IO biomarker • Journal • Chronic Lymphocytic Leukemia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Neutropenia • Novel Coronavirus Disease • Oncology • Respiratory Diseases • IGH • TP53

IMPACT OF SEX ON EFFICACY, TOLERABILITY AND PATIENT-REPORTED OUTCOMES IN FIRST-LINE THERAPY FOR CHRONIC LYMPHOCYTIC LEUKEMIA: RESULTS FROM THE CLL13/GAIA STUDY (EHA 2026) - "Background Venetoclax (V) and obinutuzumab (GA101, G), with or without ibrutinib (I), has demonstrated superiority over chemoimmunotherapy (C) with fludarabine, cyclophosphamide (FC) and rituximab (R) or R-Bendamustine as first-line treatment in fit patients (pts) with chronic lymphocytic leukemia (CLL). These findings suggest that sex may influence treatment tolerability, depth of remission and pts experience in CLL, warranting further investigation regarding treatment optimization according to sex. Figure 1 shows a) progression free survival and b) overall survival according to sex in patients treated with chemoimmunotherapy, rituximab and venetoclax, obinutuzumab and venetoclax as well as obinutzumab, venetoclax and ibrutinib as first-line treatment in chronic lymphocytic leukemia."

Clinical • Patient reported outcomes • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Richter's Syndrome • TP53

EZH2 and CREBBP mutation status identify a subset of patients who benefit from bendamustine- over CHOP/CVP-based immunochemotherapies in follicular lymphoma: Findings from the gallium trial and validation in a large international cohort (ASH 2025) - P3 | "Patientswere randomized to receive rituximab or obinutuzumab with CHOP, CVP, or bendamustine allocated bythe treating center (Marcus, 2017). Our findings suggest that EZH2 and CREBBP mutation status can inform treatment selectionin FL. Patients with CREBBP mutations and wild-type EZH2 benefit most from bendamustine withsignificantly longer PFS and similar OS; all other patients had similar PFS with either regimen but a trendtowards longer OS with CHOP/CVP. These data may indicate a distinct biology in FL with CREBBPmutations and wild-type EZH2, and support the use of simple mutation testing to guide personalizedtherapy in newly diagnosed advanced-stage patients."

Clinical • IO biomarker • Follicular Lymphoma • Hematological Malignancies • Infectious Disease • Lymphoma • CREBBP • EZH2

Aggressive Clinical Course and Treatment Refractoriness in Marginal Zone Lymphoma: A Case Report (SOHO 2026) - "The patient received 6 cycles of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). This case highlights that, despite its usual indolent behavior, MZL may rarely present with aggressive features and early refractoriness to first-line chemoimmunotherapy. Rapid progression, bulky disease, hemolytic anemia, and tumor lysis features should prompt reassessment for aggressive biology or histologic transformation. Obinutuzumab plus bendamustine may represent an effective therapeutic option in selected patients with relapsed or refractory MZL."

Case report • Clinical • IO biomarker • B Cell Lymphoma • Hematological Malignancies • Indolent Lymphoma • Lymphoma • Marginal Zone Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CCND1 • MME

A PHASE 1 STUDY EVALUATING SAFETY AND EFFICACY OF PARSACLISIB IN COMBINATION WITH BENDAMUSTINE + OBINUTUZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (CITADEL-102) (EHA 2022) - P1 | "Background Patients (pts) with follicular lymphoma (FL) generally respond well to first-line CD20-targeted therapies, such as obinutuzumab or rituximab-based regimens. Median DOR, PFS, and OS were not reached. Conclusion Parsaclisib in combination with bendamustine + obinutuzumab appears to have a manageable safety profile and demonstrated promising efficacy in pts with R/R FL."

Clinical • Combination therapy • P1 data • Febrile Neutropenia • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Metabolic Disorders • Neutropenia • Novel Coronavirus Disease • Oncology • Pneumonia • Respiratory Diseases • Thrombocytopenia • PIK3CD

First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial. (PubMed, Lancet Oncol) - P3 | "With more than 4 years of follow-up, venetoclax-obinutuzumab and venetoclax-obinutuzumab-ibrutinib significantly extended progression-free survival compared with both chemoimmunotherapy and venetoclax-rituximab in previously untreated, fit patients with chronic lymphocytic leukaemia, thereby supporting their use and further evaluation in this patient group, while still considering the higher toxicities observed with the triple combination."

Clinical • Journal • P3 data • P3 data • Acute Myelogenous Leukemia • Chronic Lymphocytic Leukemia • CNS Disorders • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Lung Cancer • Neutropenia • Oncology • Richter's Syndrome • Septic Shock • Small Cell Lung Cancer • Solid Tumor • Squamous Cell Carcinoma • TP53

ZANUBRUTINIB PLUS OBINUTUZUMAB VERSUS OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: UPDATED ANALYSIS OF THE ROSEWOOD STUDY (ICML 2023) - P2 | "A total of 114 (52.5%) pts were refractory to rituximab; 214 (98.6%) patients received prior immunochemotherapy. Prior exposure to anticancer drugs included anthracyclines (80.6%), cyclophosphamide (94.0%), and bendamustine (54.8%)... ZO demonstrated meaningful activity and a manageable safety profile in patients with heavily pretreated R/R FL, representing a potential novel therapy. Encore Abstract—previously submitted to ASCO 2023 and EHA 2023"

Clinical • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Oncology

Long-term immune reconstitution and final 1-year follow-up after fixed-duration venetoclax-obinutuzumab (VenO) in first-line (1L) chronic lymphocytic leukemia (CLL): Results from the Phase III CRISTALLO trial (ASH 2025) - "The CRISTALLO Phase III trial comparedthe efficacy and safety of fixed duration (FD) VenO vs fludarabine-cyclophosphamide-rituximab/bendamustine-rituximab (FCR/BR) in fit pts with treatment (Tx)-naïve CLL (Sharman et al. CRISTALLO demonstrated that FD VenO causes differential effects on malignant and non-malignant B-cell populations, with sustained CLL cell depletion in pts achieving uMRD alongside B-cellrecovery, delayed T-cell recovery and effective Ig reconstitution. Findings extend previous observationsand confirm that immune reconstitution can occur while maintaining deep remissions. Furthermore, finalanalysis results continue to support the efficacy and safety of FD VenO."

Clinical • P3 data • Chronic Lymphocytic Leukemia • Hematological Malignancies • Infectious Disease • Leukemia • CD24 • CD8 • FCER2 • NCAM1

Risk of Therapy-Related Myeloid Neoplasms in Patients With Chronic Lymphocytic Leukemia Treated With BTK Inhibitors: A Retrospective Multicenter Analysis Using the TriNetX Database (SOHO 2026) - "Adult patients with CLL treated with ibrutinib, acalabrutinib, or zanubrutinib were included. Patients with prior chemoimmunotherapy exposure, including fludarabine/cyclophosphamide, FCR, bendamustine/rituximab, and obinutuzumab/chlorambucil, were excluded to better isolate the long-term effects of BTKi therapy... In this large real-world TriNetX analysis of patients with CLL treated with BTK inhibitors and without prior chemoimmunotherapy exposure, therapy-related myeloid neoplasms were uncommon but increased over longer follow-up. MDS was the most frequent secondary myeloid neoplasm, followed by AML. The underlying immune dysregulation inherent to CLL, including impaired immune surveillance and defective T-cell function, may also contribute to the development of secondary malignancies in this population."

Retrospective data • Acute Myelogenous Leukemia • Chronic Lymphocytic Leukemia • Chronic Myelomonocytic Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Myeloproliferative Neoplasm • Oncology

MAINTENANCE OF HEALTH-RELATED QUALITY OF LIFE WITH VENETOCLAX-OBINUTUZUMAB VS CHEMOIMMUNOTHERAPY IN FIT PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA FROM THE PHASE 3 CRISTALLO TRIAL (EHA 2026) - P3 | "The Phase 3 CRISTALLO trial (NCT04285567) compared the efficacy and safety of fixed-duration chemotherapy- free venetoclax-obinutuzumab (VenO) vs fludarabine-cyclophosphamide-rituximab/bendamustine-rituximab (FCR/BR) in fit pts with treatment-naïve CLL without del(17p) or TP53 mutations. The lack of significant symptom interference compared with standard chemoimmunotherapy underscores the value of VenO as a patient-centric treatment that preserves HRQoL. Together with the PROs reported in the CLL14 trial and previously reported clinical outcomes, these results support the value of VenO, a fixed-duration and chemotherapy-free regimen, for fit pts with treatment-naïve CLL."

Clinical • HEOR • IO biomarker • P3 data • Chronic Lymphocytic Leukemia • CNS Disorders • Hematological Malignancies • Insomnia • Leukemia • Sleep Disorder • TP53

The impact of CHOP versus bendamustine on bone mineral density in patients with indolent lymphoma enrolled in the GALLIUM study. (PubMed, Br J Haematol) - "Standard CHOP treatment includes a high cumulative dose of prednisone, and studies have shown increased fracture risk following CHOP...Our objective was to determine the effect of obinutuzumab (G)/rituximab (R)-bendamustine versus G/R-CHOP on BMD in follicular lymphoma patients...CHOP was associated with a significant greater decrease in BMD and more frequent fractures. These results suggest that prophylaxis against BMD loss should be considered."

Journal • Follicular Lymphoma • Hematological Malignancies • Indolent Lymphoma • Lymphoma • Musculoskeletal Diseases • Non-Hodgkin’s Lymphoma • Oncology • Orthopedics

Early Chemorefractory Progression in TP53-Deleted Chronic Lymphocytic Leukemia: A Case Highlighting the Need for Targeted Therapy (SOHO 2026) - "The patient initially received 2 cycles of rituximab-bendamustine, followed by 1 cycle of R-CHOP because of ongoing clinical concern for active disease...Based on the patient's molecular profile and resistance to conventional therapy, treatment with acalabrutinib plus obinutuzumab was planned... A 66-year-old man was diagnosed with CLL based on peripheral blood immunophenotyping showing a typical clonal B-cell population positive for CD19, CD5, and CD23, with weak CD20 expression and kappa light-chain restriction. Serum immunofixation also demonstrated a kappa monoclonal band. Cytogenetic evaluation with FISH revealed 17p13.1 (TP53) deletion in all analyzed cells, indicating a veryhigh-risk disease profile."

Clinical • IO biomarker • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • CD20 • CD5 • FCER2 • TP53

GLOFITAMAB PLUS POLATUZUMAB VEDOTIN DEMONSTRATES DURABLE RESPONSES AND A MANAGEABLE SAFETY PROFILE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (ICML 2023) - P1/2 | "The CD79b targeted antibody-drug conjugate polatuzumab vedotin (Pola) is approved in combination with bendamustine and rituximab for the treatment of R/R DLBCL... Patients (pts) received obinutuzumab 1000 mg on Day (D) 1 of the first 21-day cycle (C), to mitigate risk of cytokine release syndrome (CRS)... Glofit + Pola resulted in frequent and durable responses and a manageable safety profile, with mostly low-grade CRS and low ICANS prevalence. The safety profile was consistent with that of the individual drugs. Updated efficacy, PK, and biomarker data will be presented."

Clinical • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD79B

Safety and efficacy of parsaclisib in combination with obinutuzumab and bendamustine in patients with relapsed or refractory follicular lymphoma (CITADEL-102): A phase 1 study. (PubMed, Hematol Oncol) - P1 | "Seventeen patients (65.4%) had a complete response and 3 patients (11.5%) had a partial response, for an objective response rate of 76.9%. Overall, results from CITADEL-102 suggest that the combination of parsaclisib with obinutuzumab and bendamustine did not result in unexpected safety events, with little evidence of synergistic toxicity, and demonstrated preliminary efficacy in patients with R/R FL who progressed following prior rituximab-containing regimens."

Clinical • Combination therapy • Journal • P1 data • Febrile Neutropenia • Follicular Lymphoma • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Immunology • Lymphoma • Neutropenia • Oncology • Oropharyngeal Cancer • Thrombocytopenia • CD20 • PIK3CD

LONG TERM FOLLOW-UP OF UNTREATED/RELAPSING MCL PATIENTS WITH THE IBRUTINIB, OBINUTUZUMAB, AND VENETOCLAX COMBINATION. (EHA 2023) - P1/2, P2 | "Patients who progressed were treated with Bendamustine-containing regimen (6 out of 10) and one patient received Odronextamab and anti-CD22xCD3 bispecific antibodies...Two patients prematurely discontinued the treatment, one patient had a PD at C4 and has subsequently been treated with R-CHOP, one patient relapsed after treatment completion and has been treated with Glofitamab... The Ibrutinib-Venetoclax-Obinutuzumab triplet is associated with a sustained disease control, in both R/R (4-y PFS of 50%) and newly diagnosed (4y-PFS of 80%) patients presenting with high risk-profiles (no low-MIPI patients were included in the Oasis Trial). The anti-CD20+Ibrutinib vs anti-CD20+Ibrutinib+Venetoclax combinations are currently under investigation in OASIS-II trial (NCT04802590) for untreated patients with MCL. Venetoclax, ibrutinib, Targeted therapy, Mantle cell lymphoma"

Clinical • Atrial Fibrillation • Cardiovascular • CNS Disorders • Congestive Heart Failure • Heart Failure • Hematological Malignancies • Infectious Disease • Lymphoma • Mantle Cell Lymphoma • Oncology • Pain • Rare Diseases • TP53

Antigen Escape in Relapsed/Refractory Large B-Cell Lymphoma: A Case Series of CD20 Expression Loss After CD20-Directed Therapy (SOHO 2026) - "Context: CD20-directed therapy remains foundational in the management of LBCL, yet relapsed disease may emerge with loss of CD20 expression, limiting the utility of rituximab- or obinutuzumab-based regimens or bispecific antibodies...All patients had received prior CD20-directed therapy, most commonly rituximab-containing regimens, including R-CHOP, REPOCH, R-GemOx, R-ICE, rituximab-lenalidomide, or bendamustine-rituximab. Several also received contemporary salvage approaches, including polatuzumab-based therapy, epcoritamab, tafasitamab-lenalidomide, radiation, lymphodepleting chemotherapy, and CAR-T therapy with axicabtagene ciloleucel or tisagenlecleucel... CD20-negative conversion is a clinically consequential pattern of relapse in heavily pretreated LBCL. This series highlights the importance of repeat biopsy at progression to reassess targetable antigen expression and avoid ineffective recycling of CD20-directed therapy. Antigen reassessment should inform..."

Clinical • IO biomarker • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • High-grade B-cell lymphoma • Indolent Lymphoma • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD19 • CD20 • CD22

Safety and efficacy of atezolizumab with obinutuzumab and bendamustine in previously untreated follicular lymphoma. (PubMed, Blood Adv) - P1/2 | "Obinutuzumab (G)-chemoimmunotherapy demonstrated improved progression-free survival (PFS) versus rituximab-based chemoimmunotherapy in patients with previously untreated follicular lymphoma (FL) in the GALLIUM trial. Particularly due to the unfavorable safety profile, this regimen cannot be recommended in patients with previously untreated FL. This trial is registered at www.clinicaltrials.gov as NCT02596971."

Journal • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Oncology • PD-L1